Dergiler / Türk Üroloji Dergisi/Turkish Journal of Urology / 2005 / Cilt: 31 - Sayı: 4

Mesane kanserinde serum immünoglobulin (IgA, IgE, IgG, IgM), kompleman (C3, C4) ve C-reaktif protein düzeyi

Evaluation of serum levels of immunoglobulins (IgA, IgE, IgG, IgM), complement (C3, C4) and C-reactive protein in bladder cancer: A controlled prospective clinical trial

Sayfa
495–502
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Kesin sonuçlar için daha geniş kapsamlı ve uzun dönemli çalışmalara ihtiyaç vardır.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Bu çalışmamızda mesane tümörlü hastaları serum immünoglobulin, kompleman ve C-reaktif protein düzeyleri açısından kontrollü değerlendirilmesini amaçladık.
📊
Temel Bulgular & Veri:Kan ve idrar örnekleri ameliyat öncesinde hem kontrol hem de tümör hastalarından ve ameliyat sonrası 1. ve 3. aylarda sadece tümör hastalarından alındı.
💡
Sonuç & Katkı:Kesin sonuçlar için daha geniş kapsamlı ve uzun dönemli çalışmalara ihtiyaç vardır.
🔬Tür:Araştırma Makalesi
📍Kapsam:20 hasta
⚙️Değişkenler:C-reaktif protein · Kompleman C4 · İleriye dönük çalışma

Özet

Bu çalışmamızda mesane tümörlü hastaları serum immünoglobulin, kompleman ve C-reaktif protein düzeyleri açısından kontrollü değerlendirilmesini amaçladık. Kan ve idrar örnekleri ameliyat öncesinde hem kontrol hem de tümör hastalarından ve ameliyat sonrası 1. ve 3. aylarda sadece tümör hastalarından alındı. Tümör (20 hasta) ve kontrol (41 hasta) hastalarında ortalama yaş sırasıyla 64.2±9.9 ve 63.7±8.9 idi. Gruplar arasında üriner enfeksiyon insidansında istatistiksel farklılık yoktu. Tümör grubundaki IgA-E-G-C3 ve CRP düzeyleri kontrol grubundan belirgin yüksek, C4 düzeyi düşük ve IgM düzeyi kontrolden farksızdı. Ancak rezeksiyonu takiben hepsi çok belirgin olarak azaldı. Üçüncü ayda mesanesinde tümör olan 6 hastanın C4 dışında bütün serum düzeyleri tümör negatiflerle benzerdi. IgA-E-G-C3 ve CRP'nin tedavi öncesi serum değerleri primer tümörün tanısında özgül, duyarlı, ve prediktif gibi görünse de, bunların hiçbirisinin hastaların takibinde faydalı bulunmaması, tümörde tanısal olmadıklarını ortaya koymaktadır. İki grupta da enfeksiyon ile serum düzeyleri arasında ilişki tespit edilmedi. Tümörün patolojik evresi ve farklılaşma derecesi ile immünoglobulin ve C4 düzeyleri arasında ilişki yoktu. Ancak evre ile C3 ve CRP arasında pozitif ilişki mevcuttu. Rezeksiyon sonrası sadece izlenen (6) ve kemoterapi (5) veya intravazikal BCG (9) uygulanan hastaların 3. ay serum düzeyleri arasında C4 dışında fark yoktu. Sadece C4 düzeyi kemoterapi alanlarda BCG grubundan daha yüksekti. Serum IgA, IgG, IgE, IgM, C3, C4 ve CRP düzeylerinin belirlenmesi primer mesane kanserinin tanı ve takibinde faydasız gibi görünmektedir. Kesin sonuçlar için daha geniş kapsamlı ve uzun dönemli çalışmalara ihtiyaç vardır.

Abstract

Introduction: During the management of a patient with bladder cancer, the aim of a clinician is to diagnose the tumor with a most sensitive and least invasive method. Cystoscopy and urine cytology are standard practice in following these patients; however, cystoscopy is invasive, and urine cytology has low sensitivity. Therefore, this study aims to evaluate the diagnostic and prognostic value of the humoral immunity in the bladder cancer patients by means of measuring serum levels of immunoglobulins, complements and Creactive protein pre and postoperatively compared with controls. Materials and Methods: Blood and urine samples were taken from both tumor and control patients preoperatively and from only tumor patients at postoperative 1 and 3 months. Urine samples were examined immediately for microscopic examination and culturing. Serum samples were stored at -80°C in a deep freeze till processing and assessed blindly by same person at the end of the study. Patients who preoperatively received intravesical BCG instillation therapy, radiotherapy or chemotherapy for their bladder carcinoma diseases were not included in tumor group. Patients who underwent a transurethral procedure for a nonneoplastic genitourinary disease and did not have any documented cancer, served as controls. Results: Mean ages of tumor (20 pts; 1 female, 19 males) and control (41 pts; 3 females, 38 males) patients were 64.2±9.9 and 63.7±8.9, respectively (p=0.846). All tumor patients completed 3 months of follow-up. There was no statistical difference in urinary infection incidences between tumor and control groups. Serum IgA, IgE, IgG, C3 and CRP levels were statistically significantly higher in tumor group than in control group, while lower C4 and indifferent IgM levels were present in tumor group compared to control. However following tumor resection, all of them decreased very significantly. All serum levels, except C4, of 6 patients with visible tumor in their bladders at postoperative 3rd month were similar to those of tumor-negative patients. Although preoperative high levels of IgA, IgE, IgG, C3 and CRP appeared as sensitive, specific and predictive in primary bladder tumor diagnosis, post-treatment levels of any of those above were not found as useful in follow-up, suggesting that these were not diagnostic and prognostic parameters for bladder tumor. No correlation was established between infection and serum levels in both groups since there were not statistically significant differences in serum immunoglobulins, complements and CRP levels between the patients with and without urinary infection in each group. Pathologic stage and grade of the tumor did not correlate with immunoglobulin and C4 levels. However, there was a significant positive correlation between stage and C3 or CRP. There were no differences between the 3rd month serum levels of patients who took no therapy (6 pts) or chemotherapy (5 pts) or intravesical BCG (9 pts) after resections, except C4 which was higher in patients who took chemotherapy than in those who took BCG. Conclusion: Although serum immunoglobulins, complements and CRP appear to be nondiagnostic for primary bladder carcinoma, wider studies with longer follow-up and higher patient population are necessary for more definitive conclusions.

🔖

Bu Makaleye Atıf Yap

KILIÇ, S., BAYRAKTAR, M., BAYRAKTAR, N., ERGİN, H., BEYTUR, A., EĞRİ, M. (2005). Mesane kanserinde serum immünoglobulin (IgA, IgE, IgG, IgM), kompleman (C3, C4) ve C-reaktif protein düzeyi. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 31 - Sayı: 4, 495–502. https://ajindex.com/articles/329012

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Messing EM, Catalona W: Urothelial tumors of the urinary tract; in Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds): Campbells Urology 7th edition vol. 3, 2327- 2410, 1998
  2. Eijan AM, Piccardo I, Riveros MD, et al: Nitric oxide in patients with transitional bladder cancer. J Surg Oncol. 81: 203-208, 2002
  3. Syrigos KN, Harrington KJ, Pignatelli M: Role of adhesion molecules in bladder cancer: an important part of the jigsaw. Urology, 53: 428-434, 1999
  4. Sobin LH, Wittehind CH: TNM classification of Malignant Tumours, Wiley-Liss, New York, 1997
  5. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O’Sullivan B, Yarbro JW: AJCC Cancer Staging Manual, Lippincott, Philadelphia, 1997
  6. Yüceer N, Arasıl E, Temiz C: Serum immunoglobulins in brain tumours and lumbar disc diseases. Neuroport. 11: 279-281, 2000
  7. Hakala TR, Lange PH, Castro AE, et al: Lymphocyte antibody interaction in cytotoxicity against human transitional cell carcinoma. J Urol. 113: 663-667, 1975
  8. Vinzenz K, Pavelka R, Schönthal E, Zekert F: Serum immunoglobulin levels in patients with head and neck 1986
  9. Vijayakumar T, Ankathil R, Remani P, et al: Serum immunoglobulins in patients with carcinoma of the oral cavity, uterine cervix and breast. Cancer Immunol Immunother. 22: 76-79, 1986
  10. Jacobs D, Landon J, Houri M, Merrett TG: Circulating levels of immunoglobulin E in patients with cancer. Lancet, 2: 1059-1061, 1972
  11. Schmidt JD, Feldbush TL, Weinstein SH, Bonney WW: Serum immunoglobulins in genitourinary malignnancies. J Urol. 115: 293-295, 1976
  12. Merrin C, Han T: İmmüne response in bladder cancer. J Urol. 111: 170-172, 1974
  13. Martinez-Pineiro JA, Muntanola P, Hidalgo L: Immunological evaluation in patients with urological cancers. Eur Urol. 3: 159-162, 1977
  14. Dostalova O, Schon E, Wagnerova M, et al: Serum immunoglobulin levels in cancer patients. I. Serum immunoglobulins and primary tumor localization. Neoplasma, 22: 539-546, 1975
  15. Rossel M, Billerey C, Bittard H, et al: Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma. Urol Res. 19: 361-366, 1991
  16. Kronberger L, Steinschifter W, Weblacher M, et al: Selective decrease of serum immunoglobulin G1 as marker for early stages of invasive breast cancer. Breast Cancer Res Treat. 64: 193-199, 2000
  17. Schauenstein E, Reiter M, Gombotz H, List W: Labile disulfide bonds and free thiol groups in human IgG. II. Characteristics changes i